Regarding to the mean serum survivin and fibulin-3 levels in the included patients with lung cancer or MPM in terms of tumor stage, the mean serum survivn and fibulin-3 (pg/ml) levels didn’t significantly differ among lung cancer patients with stage II (636.4 ± 161.0 and 3.146 ± 1.68, respectively) or III (424.7 ± 219.0 and 1.785 ± 0.68, respectively) or IV (774.3 ± 336.4 and 4.291 ± 2.54, respectively) with P>0.05 for all. This evidence concerns the gene BIRC5 and lung cancer.